This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
JNJ Beats on Q2 Earnings, Ups View: ETFs to Buy
by Sweta Killa
The company recorded 164 million in COVID-19 vaccine sales in the second quarter, up 64% from the first, and aims to fetch $2.5 billion in sales by the end of the year.
UnitedHealth's Solid Q2 Earnings Put These ETFs in Focus
by Sweta Killa
UnitedHealth reported better-than-expected second-quarter 2021 results, breezing past the Zacks Consensus Estimate for both earnings and revenues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
5 ETFs That Are Investors' Favorites to Start May
by Sweta Killa
Overall ETFs gathered about $15.3 billion capital last week, bringing in year-to-date inflows of $335.7 billion.
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
Healthcare ETFs in Focus Post JNJ's Q1 Earnings Results
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat and outpaced revenue estimates. However, the company tightened its full-year guidance.
Are Healthcare ETFs Poised for a Comeback?
by Sanghamitra Saha
Decent earnings growth picture and valuation as well as solid deals activities have been favoring healthcare sector at the current level.
Healthcare ETFs to Gain on UnitedHealth's Strong Q1 Earnings
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected first-quarter 2021 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full-year earnings outlook.
5 ETFs to Make the Most of Thermo Fisher Deal to Buy PPD
by Sweta Killa
Thermo Fisher Scientific (TMO) has agreed to buy the healthcare testing company PPD Inc. (PPD) for $17.4 billion in cash.
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs that can see adverse impacts as Johnson & Johnson's coronavirus vaccine sees a setback amid the worsening pandemic conditions.
4 Sector ETFs to Watch for Gains in Q2
by Sanghamitra Saha
The earnings expectations for the S&P 500 companies for Q2 is now a rise of 49.9% on 14.7% higher revenues.
J&J ETFs to Shine Bright as FDA Grants EUA for Coronavirus Vaccine
by Sweta Jaiswal, FRM
Johnson & Johnson's receipt of EUA for its single-shot COVID-19 vaccine will strengthen the U.S. government's position in the fight against the pandemic and benefit ETFs with high exposure to the pharmaceutical giant.
How to Trade USFDA's EUA to J&J Vaccine With ETFs
by Sanghamitra Saha
On Feb 27, the United States sanctioned Johnson & Johnson's COVID-19 vaccine for emergency use, giving the nation a third vaccine to fight the outbreak, after BioNTech/Pfizer and Moderna.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
by Sweta Killa
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high.
Healthcare ETFs in Focus on UnitedHealth's Solid Q4 Earnings
by Sweta Killa
UnitedHealth Group (UNH) reported better-than-expected fourth-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.
4 Sector ETFs & Stocks to Bet on Q4 Earnings
by Sweta Killa
Sectors with positive earnings growth in Q4 include autos (86.3% earnings growth), construction (27.2%), basic materials (7.6%), medical (6.3%), and aerospace (4.4%).
The Biden Trades: Global Week Ahead
by John Blank
Betting on a fiscal boost under President-elect Joe Biden, investors pushed the 10-year TIPS breakeven inflation rate above 2% for the first time since 2018.
ETFs to Gain on UnitedHealth and Change Healthcare Deal
by Sweta Killa
UnitedHealth agreed to buy Change Healthcare for $7.84 billion in cash.
6 Secret Santa ETFs to Add Cheer to Your Portfolio
by Sweta Killa
While most of the ETFs have been surging over the past month, there are some hidden gems or Secret Santa as we call them that could surprise investors with big returns this Christmas based on the current trends.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH